US stock futures little changed as investors await more earnings reports
The broad S&P 500 and tech-heavy Nasdaq scored record highs to start the week amid solid earnings reports from Domino's Pizza, Cleveland-Cliffs and Verizon.
Of the more than 60 S&P 500 companies that have reported, more than 85% of those topping analysts' estimates, according to FactSet data. Analysts on average expected S&P 500 companies to report a 6.7% increase in earnings for the second quarter, with big technology companies driving much of that gain, according to LSEG I/B/E/S.
Philip Morris International, Coca-Cola and Lockheed Martin are among those slated to report before the market opens. However, the main events are midweek when Tesla and Alphabet report results. Investors will be keen to dissect the earnings reports for signs of how President Donald Trump's tariffs have hit the economy and corporate spending.
At 6 a.m. ET, futures linked to the blue-chip Dow were at 0%, while S&P 500 futures slipped -0.11% and Nasdaq futures dropped -0.27%.
Federal Reserve Chairman Jerome Powell is also scheduled to speak at a conference in Washington DC as the stock market opens.
Corporate news
Goldman Sachs held talks for a roughly $25 billion takeover of wealth management firm Northern Trust earlier this year and almost closed a $6 billion deal for Cliffwater, Semafor reported.
NXP Semiconductors' second-quarter results topped analysts' forecasts.
Steel Dynamics' second-quarter results missed expectations.
Zions Bancorp reported second-quarter earnings per share above Wall Street's estimates.
Sarepta Therapeutics said it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatment died. Initially, the company refused to do so after a FDA request.
Medora Lee is a money, markets, and personal finance reporter at USA TODAY. You can reach her at mjlee@usatoday.com and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday.
This article originally appeared on USA TODAY: US stock futures little changed as investors await earnings reports
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Jefferies Group's Strategic Moves: SPDR S&P 500 ETF Trust Takes Center Stage with 2. ...
Analyzing Jefferies Group (Trades, Portfolio)'s Latest 13F Filing for Q2 2025 Introduction to Jefferies Group (Trades, Portfolio) Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for the second quarter of 2025, offering a glimpse into its strategic investment decisions. Founded by Harvard graduates Ian Cummings and Joseph S. Steinberg, the company initially took control of Talcott National Corporation in 1980, renaming it Leucadia National. In 2013, Jefferies Group (Trades, Portfolio) acquired the company, with Richard Handler stepping in as CEO. By 2018, it was rebranded as Jefferies Financial Group (JEF). Jefferies Group (Trades, Portfolio) operates through various subsidiaries, engaging in investment banking, telecommunications, healthcare services, and more. The firm follows a value investing approach, focusing on acquiring distressed companies at discounted prices, revitalizing them, and selling for profit. Their strategy emphasizes not overpaying, investing in essential products or services, and valuing sheltered earnings over taxed ones. Summary of New Buy Jefferies Group (Trades, Portfolio) added a total of 210 stocks, among them: The most significant addition was Marex Group PLC (NASDAQ:MRX), with 1,038,967 shares, accounting for 0.35% of the portfolio and a total value of $41.01 million. The second largest addition to the portfolio was Couchbase Inc (NASDAQ:BASE), consisting of 1,524,681 shares, representing approximately 0.32% of the portfolio, with a total value of $37.17 million. The third largest addition was uniQure NV (NASDAQ:QURE), with 2,095,931 shares, accounting for 0.25% of the portfolio and a total value of $29.22 million. Key Position Increases Jefferies Group (Trades, Portfolio) also increased stakes in a total of 274 stocks, among them: The most notable increase was SPDR S&P 500 ETF Trust (SPY), with an additional 498,285 shares, bringing the total to 1,318,891 shares. This adjustment represents a significant 60.72% increase in share count, a 2.65% impact on the current portfolio, with a total value of $814,876,590. The second largest increase was iShares Russell 2000 ETF (IWM), with an additional 283,563 shares, bringing the total to 849,018. This adjustment represents a significant 50.15% increase in share count, with a total value of $183,209,620. Summary of Sold Out Jefferies Group (Trades, Portfolio) completely exited 556 holdings in the second quarter of 2025, as detailed below: Lions Gate Entertainment Corp (NYSE:LGF.A): Jefferies Group (Trades, Portfolio) sold all 3,725,000 shares, resulting in a -0.3% impact on the portfolio. Sabra Health Care REIT Inc (NASDAQ:SBRA): Jefferies Group (Trades, Portfolio) liquidated all 1,466,000 shares, causing a -0.23% impact on the portfolio. Key Position Reduces Jefferies Group (Trades, Portfolio) also reduced positions in 318 stocks. The most significant changes include: Reduced Apple Inc (NASDAQ:AAPL) by 532,930 shares, resulting in a -80.04% decrease in shares and a -1.06% impact on the portfolio. The stock traded at an average price of $202.27 during the quarter and has returned 9.70% over the past 3 months and -6.49% year-to-date. Reduced Alphabet Inc (NASDAQ:GOOGL) by 384,391 shares, resulting in a -96.97% reduction in shares and a -0.53% impact on the portfolio. The stock traded at an average price of $163.55 during the quarter and has returned 26.75% over the past 3 months and 6.94% year-to-date. Portfolio Overview At the second quarter of 2025, Jefferies Group (Trades, Portfolio)'s portfolio included 1,118 stocks. The top holdings included 7.01% in SPDR S&P 500 ETF Trust (SPY), 1.58% in iShares Russell 2000 ETF (IWM), 1.25% in INVESCO QQQ Trust (NASDAQ:QQQ), 1.02% in SPDR Biotech ETF (XBI), and 1.01% in Mastercard Inc (NYSE:MA). The holdings are mainly concentrated in all 11 industries: Healthcare, Financial Services, Technology, Industrials, Energy, Consumer Cyclical, Communication Services, Consumer Defensive, Real Estate, Utilities, and Basic Materials. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 minutes ago
- Yahoo
Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...
Exploring the Latest Investment Strategies of Vanguard Health Care Fund (Trades, Portfolio) Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the second quarter of 2025, shedding light on its strategic investment decisions during this period. Managed by Jean M. Hynes, CFA, CEO of Wellington Management Company, the fund is renowned for its focus on long-term capital appreciation within the health care sector. Wellington Management Company, established in 1928, is one of the oldest and most respected institutional investment managers in the United States, advising the Vanguard Health Care Fund (Trades, Portfolio) since 1984. The fund aims to maintain a diversified exposure across five primary subsectors: health services, medical products, specialty pharmaceuticals, major pharmaceuticals, and international markets. Its investment philosophy emphasizes companies with robust balance sheets, strong management, and potential for innovative products that could drive above-average growth in revenue and earnings. The fund's contrarian style often leads to purchasing stocks after negative events have caused a decline in share price. Summary of New Buy Vanguard Health Care Fund (Trades, Portfolio) added a total of eight stocks, with the most significant addition being Johnson & Johnson (NYSE:JNJ). The fund acquired 4,660,244 shares, which now account for 2.05% of the portfolio, with a total value of $711.85 million. The second largest addition was Roche Holding AG (XSWX:ROG), consisting of 1,677,044 shares, representing approximately 1.58% of the portfolio, with a total value of CHF 547,420,130. The third largest addition was Gilead Sciences Inc (NASDAQ:GILD), with 4,823,087 shares, accounting for 1.54% of the portfolio and a total value of $534.74 million. Key Position Increases Vanguard Health Care Fund (Trades, Portfolio) also increased stakes in a total of 16 stocks. The most notable increase was in Elevance Health Inc (NYSE:ELV), with an additional 507,005 shares, bringing the total to 1,700,286 shares. This adjustment represents a significant 42.49% increase in share count, a 0.57% impact on the current portfolio, with a total value of $661.34 million. The second largest increase was in Cencora Inc (NYSE:COR), with an additional 501,886 shares, bringing the total to 2,279,215. This adjustment represents a significant 28.24% increase in share count, with a total value of $683.42 million. Summary of Sold Out Vanguard Health Care Fund (Trades, Portfolio) completely exited 12 holdings in the second quarter of 2025. Notable exits include Blueprint Medicines Corp (BPMC), where the fund sold all 1,362,970 shares, resulting in a -0.32% impact on the portfolio. Another significant exit was Surgery Partners Inc (NASDAQ:SGRY), with the liquidation of all 4,602,252 shares, causing a -0.29% impact on the portfolio. Key Position Reduces Vanguard Health Care Fund (Trades, Portfolio) also reduced its position in 45 stocks. The most significant changes include a reduction in Novartis AG (XSWX:NOVN) by 5,691,220 shares, resulting in a -49.44% decrease in shares and a -1.66% impact on the portfolio. The stock traded at an average price of CHF 93.19 during the quarter and has returned 8.24% over the past three months and 13.88% year-to-date. Another notable reduction was in Edwards Lifesciences Corp (NYSE:EW) by 6,663,224 shares, resulting in a -37.32% reduction in shares and a -1.27% impact on the portfolio. The stock traded at an average price of $74.55 during the quarter and has returned 2.89% over the past three months and 4.93% year-to-date. Portfolio Overview As of the second quarter of 2025, Vanguard Health Care Fund (Trades, Portfolio)'s portfolio included 81 stocks. The top holdings included 10.78% in Eli Lilly and Co (NYSE:LLY), 6.49% in AstraZeneca PLC (LSE:AZN), 5.56% in UnitedHealth Group Inc (NYSE:UNH), 4.52% in Merck & Co Inc (NYSE:MRK), and 4.35% in Boston Scientific Corp (NYSE:BSX). The holdings are mainly concentrated in one of the 11 industries: Healthcare. This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein. This article first appeared on GuruFocus.
Bloomberg
9 minutes ago
- Bloomberg
Bond Rally Extends, Trump Delivers Putin Warning, Orban's Grip Slipping
Your morning briefing, the business news you need in just 15 minutes. On today's podcast: (1) US Treasuries held onto gains after traders boosted bets that the Federal Reserve will cut interest rates at its next meeting. (2) President Donald Trump said he may name the next Federal Reserve chair 'a little bit early' and added that he was down to three or four potential candidates as he looks for a successor to Jerome Powell. (3) US President Donald Trump warned he would impose 'very severe consequences' if Vladimir Putin didn't agree to a ceasefire agreement later this week, following a call with European leaders ahead of his meeting with the Russian president. (4) Apple is plotting its artificial intelligence comeback with an ambitious slate of new devices, including robots, a lifelike version of Siri, a smart speaker with a display and home-security cameras. (5) Short sellers are betting against Greggs Plc at levels not seen since the global financial crisis, as the UK bakery chain struggles to convince investors that opening more shops will boost lackluster sales. (6) Bloomberg reports into how Tisza, an upstart Hungarian political movement, is making surprising gains against Viktor Orban's grip on the country's politics.
